- Teladoc Health reported Q4 2018 results that beat the top- and bottom-line estimates. Additionally, the company reported strong financial results and growth metrics for full-year 2018.
- However, management's 2019 guidance was not well received by the market. But, in my opinion, the market overreacted to what I consider a good but not great outlook.
- I am long Teladoc Health, and I plan to stay long the stock.
Teladoc Health ($TDOC) reported better-than-expected Q4 2018 financial results after the market close on February 27, 2019, but the stock finished the next trading day down by over 6%. TDOC shares are, however, still outperforming the broader market by a wide margin over the last year.
The stock has been extremely volatile over the recent past, and this will likely be the case for 2019, too. However, I believe that the risk for TDOC's shares is currently to the upside, of course, if you are willing (and able) to hold onto your stock for at least the next two to three years, because Teladoc's most recent operating results (and management commentary) showed that the bull case remains strong.
Read more here.